Business
Alkermes to Participate in the Jefferies Healthcare Conference
DUBLIN, June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies
About this update from Alkermes Plc
[{"type":"text","content":"DUBLIN, June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET (7:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.\nAbout Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.\nContact:Alex BraunInvestor Relations+1 781 296 8493\n\n \n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-jefferies-healthcare-conference-301558669.html\nSOURCE Alkermes plc","length":2921,"tagName":"div"}]